Product Description
Mechanisms of Action: 5-HT4 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Atrial Fibrillation|Heart Failure
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2005-004487-22 | P2 |
Completed |
Heart Failure |
2007-07-17 |
2022-03-12 |
Treatments |
|
| NCT00041496 | P2 |
Completed |
Atrial Fibrillation |
2003-12-01 |
2019-03-21 |
Treatments |
|
| BMI 001 / SMR-1389 | P2 |
Completed |
Heart Failure |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/09/2023 |
PubMed |
The effect of ginger extract on cisplatin-induced acute anorexia in rats. |
|
09/01/2023 |
PubMed |
5-Hydroxytryptamine: a potential therapeutic target in amyotrophic lateral sclerosis. |